Free Trial
→ 625,000% Gain (From Crypto Swap Profits) (Ad)

10 Best Penny Stocks to Buy Now - 2 of 10

Slide 2
Back to 1
Continue to 3
 
Back to 1
Continue to 3
 

CytomX Therapeutics (NASDAQ:CTMX)

Number of Upgrades from Top-Ranked Analysts
5 (in the last 90 days)
Consensus Rating
Moderate Buy
Rating Score
2.5
Ratings Breakdown
3 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$5.77 (477.3% Upside)

About CytomX Therapeutics

CytomX Therapeutics logoCytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
11/11/2024HC WainwrightReiterated RatingNeutral
9/13/2024HC WainwrightReiterated RatingNeutral
8/22/2024HC WainwrightReiterated RatingNeutral
6/27/2024HC WainwrightReiterated RatingNeutral
5/28/2024Piper SandlerUpgradeNeutral ➝ Overweight$2.25 ➝ $3.50
5/9/2024BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$3.25 ➝ $3.59
5/9/2024HC WainwrightReiterated RatingNeutral
5/9/2024WedbushUpgradeNeutral ➝ Outperform$3.00 ➝ $8.00
5/6/2024Jefferies Financial GroupUpgradeHold ➝ Buy$2.50 ➝ $8.00
5/1/2024BMO Capital MarketsReiterated RatingMarket Perform ➝ Market Perform$3.25
Slide 2
Back to 1
Continue to 3
 

625,000% Gain (Ad)

Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.

>> Dive into the Workshop Here

More From MarketBeat
Bill Gates’s Next Big AI Bet: Stargate
In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...
Brownstone Research | Sponsored
7 Consumer Discretionary Stocks That Will Continue to Rally
Consumer discretionary stocks appear to be among the winners from the ongoing Trump trade following the U.S. p...
MarketBeat
Top "Sleeping Giant" Crypto In The Market Now
Top "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your fi...
Crypto 101 Media | Sponsored
7 Best Chinese Stocks to Own Before the Bubble Bursts
The geopolitical relationship between the United States and China is volatile and complicated. But the importa...
MarketBeat
Tim Sykes’ Urgent Trade Alert: “Make this move now”
WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...
Timothy Sykes | Sponsored
7 Russell 2000 Stocks to Buy as Sector Rotation Begins
The myth of the Russell 2000 index is that it's a small-cap index. In reality, the index focuses on both small...
MarketBeat